• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

非肿瘤性乳腺实质的组织病理学特征不能预测浸润性乳腺癌患者的BRCA突变状态。

Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer.

作者信息

Bayraktar Soley, Qiu Hongming, Liu Diane, Shen Yu, Gutierrez-Barrera Angelica M, Arun Banu K, Sahin Aysegul A

机构信息

Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Biomark Cancer. 2015 Aug 18;7:39-49. doi: 10.4137/BIC.S29716. eCollection 2015.

DOI:10.4137/BIC.S29716
PMID:26327783
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4541461/
Abstract

BACKGROUND

Several studies have evaluated histologic features of non-neoplastic breast parenchyma in patients with BRCA1/2 mutations, but the results are conflicting. The limited data suggest a much higher prevalence of high-risk precursor lesions in BRCA carriers. Therefore, we designed this study to compare the clinicopathological characteristics of peritumoral benign breast tissue in patients with and without deleterious BRCA mutations.

METHODS

Women with breast cancer (BC) who were referred for genetic counseling and underwent BRCA genetic testing in 2010 and 2011 were included in the study.

RESULTS

Of the six benign histological features analyzed in this study, only stromal fibrosis grade 2/3 was found to be statistically different, with more BRCA noncarriers having stromal fibrosis grade 2/3 than BRCA1/2 carriers (P = 0.04).

CONCLUSION

There is no significant association between mutation risk and the presence of benign histologic features of peritumoral breast parenchyma.

摘要

背景

多项研究评估了携带BRCA1/2突变患者非肿瘤性乳腺实质的组织学特征，但结果相互矛盾。有限的数据表明BRCA携带者中高危前驱病变的患病率要高得多。因此，我们设计了本研究，以比较有和没有有害BRCA突变的患者瘤周良性乳腺组织的临床病理特征。

方法

纳入2010年和2011年因遗传咨询转诊并接受BRCA基因检测的乳腺癌女性患者。

结果

在本研究分析的六种良性组织学特征中，仅发现2/3级间质纤维化在统计学上存在差异，BRCA非携带者中2/3级间质纤维化的比例高于BRCA1/2携带者（P = 0.04）。

结论

突变风险与瘤周乳腺实质良性组织学特征的存在之间无显著关联。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1525/4541461/731206ce3fad/bic-7-2015-039f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1525/4541461/24d36bc3aa55/bic-7-2015-039f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1525/4541461/e2383872685c/bic-7-2015-039f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1525/4541461/2254c3b9ae24/bic-7-2015-039f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1525/4541461/731206ce3fad/bic-7-2015-039f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1525/4541461/24d36bc3aa55/bic-7-2015-039f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1525/4541461/e2383872685c/bic-7-2015-039f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1525/4541461/2254c3b9ae24/bic-7-2015-039f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1525/4541461/731206ce3fad/bic-7-2015-039f4.jpg

相似文献

1
Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer.非肿瘤性乳腺实质的组织病理学特征不能预测浸润性乳腺癌患者的BRCA突变状态。
Biomark Cancer. 2015 Aug 18;7:39-49. doi: 10.4137/BIC.S29716. eCollection 2015.
2
BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.日本原位导管癌女性中的BRCA1/BRCA2基因突变
Mol Genet Genomic Med. 2019 Mar;7(3):e493. doi: 10.1002/mgg3.493. Epub 2019 Jan 16.
3
Prevalence of BRCA1 and BRCA2 Mutations Among High-risk Bahraini Patients with Breast Cancer.BRCA1 和 BRCA2 基因突变在高风险巴林乳腺癌患者中的流行率。
Gulf J Oncolog. 2023 May;1(42):22-25.
4
The clinicopathological and MRI features of patients with BRCA1/2 mutations in familial breast cancer.家族性乳腺癌中BRCA1/2突变患者的临床病理及MRI特征
Gland Surg. 2021 Jan;10(1):262-272. doi: 10.21037/gs-20-596.
5
Ductal carcinoma in situ in BRCA mutation carriers.携带BRCA基因突变者的导管原位癌
J Clin Oncol. 2007 Feb 20;25(6):642-7. doi: 10.1200/JCO.2005.04.0345. Epub 2007 Jan 8.
6
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.BRCA阳性和BRCA阴性乳腺癌患者的临床和病理特征。
J Clin Oncol. 2008 Sep 10;26(26):4282-8. doi: 10.1200/JCO.2008.16.6231.
7
Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study.基于BRCA突变谱的高危乳腺癌患者的临床和病理特征：一项回顾性研究
Eur J Breast Health. 2021 Mar 31;17(2):123-127. doi: 10.4274/ejbh.galenos.2020.6346. eCollection 2021 Apr.
8
Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.BRCA 突变携带者的双侧预防性乳房切除术：外科医生需要了解的内容。
Ann Ital Chir. 2019;90:1-2.
9
Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.遗传性乳腺癌患者乳腺实质的病理特征，包括BRCA1和BRCA2突变携带者。
Cancer. 2003 Jan 1;97(1):1-11. doi: 10.1002/cncr.11048.
10
Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.目前针对乳腺癌患者进行BRCA检测的指南不足以检测出所有的突变携带者。
BMC Cancer. 2017 Jun 21;17(1):438. doi: 10.1186/s12885-017-3422-2.

引用本文的文献

1
Tumor Microenvironment Features as Predictive Biomarkers in Metastatic Differentiated Thyroid Cancer and Their Relationship With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) Metabolic Parameters.肿瘤微环境特征作为转移性分化型甲状腺癌的预测生物标志物及其与18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（18F-FDG PET/CT）代谢参数的关系
Cureus. 2023 Sep 5;15(9):e44751. doi: 10.7759/cureus.44751. eCollection 2023 Sep.

本文引用的文献

1
Lobulitis in nonneoplastic breast tissue from breast cancer patients: association with phenotypes that are common in hereditary breast cancer.乳腺癌患者非肿瘤性乳腺组织中的小叶炎：与遗传性乳腺癌中常见表型的关联。
Hum Pathol. 2014 Jan;45(1):78-84. doi: 10.1016/j.humpath.2013.08.008. Epub 2013 Oct 21.
2
Benign breast disease, mammographic breast density, and the risk of breast cancer.良性乳腺疾病、乳腺 X 线摄影密度与乳腺癌风险。
J Natl Cancer Inst. 2013 Jul 17;105(14):1043-9. doi: 10.1093/jnci/djt124. Epub 2013 Jun 6.
3
Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.
BRCA 基因突变携带者和非携带者乳腺癌新辅助全身治疗的反应：单中心经验。
J Clin Oncol. 2011 Oct 1;29(28):3739-46. doi: 10.1200/JCO.2011.35.2682. Epub 2011 Sep 6.
4
Expanding the criteria for BRCA mutation testing in breast cancer survivors.扩大乳腺癌幸存者中 BRCA 基因突变检测的标准。
J Clin Oncol. 2010 Sep 20;28(27):4214-20. doi: 10.1200/JCO.2010.28.0719. Epub 2010 Aug 23.
5
The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers.乳腺癌病理学对预测 BRCA 携带者突变风险的统计模型的贡献。
Fam Cancer. 2010 Dec;9(4):545-53. doi: 10.1007/s10689-010-9362-5.
6
Pattern of breast masses in Lagos: a private health facility review of 189 consecutive patients.拉各斯乳腺肿块的模式：一家私立医疗机构对189例连续患者的回顾。
Nig Q J Hosp Med. 2010 Jan-Mar;20(1):38-41. doi: 10.4314/nqjhm.v20i1.58015.
7
Histological features of extratumoral breast lesions as a predictive factor of familial breast cancer.肿瘤旁乳腺病变的组织学特征作为家族性乳腺癌的预测因子。
Oncol Rep. 2010 Jun;23(6):1641-5. doi: 10.3892/or_00000806.
8
Assessing women at high risk of breast cancer: a review of risk assessment models.评估高乳腺癌风险女性：风险评估模型回顾。
J Natl Cancer Inst. 2010 May 19;102(10):680-91. doi: 10.1093/jnci/djq088. Epub 2010 Apr 28.
9
High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers.与BRCA1/2相关的乳腺癌相邻的癌前病变患病率高。
Cancer Prev Res (Phila). 2009 Feb;2(2):122-7. doi: 10.1158/1940-6207.CAPR-08-0050. Epub 2009 Jan 27.
10
Lobule type and subsequent breast cancer risk: results from the Nurses' Health Studies.小叶类型与后续患乳腺癌风险：护士健康研究的结果
Cancer. 2009 Apr 1;115(7):1404-11. doi: 10.1002/cncr.24167.